

Samuel Lara-González,† Jens J.  
Birktoft and Catherine L.  
Lawson\*

Department of Chemistry and Chemical Biology,  
Rutgers University, 610 Taylor Road,  
Piscataway, NJ 08854, USA

† Current address: Laboratorio Nacional de  
Genómica para la Biodiversidad, CINVESTAV  
Irapuato, Km 9.6 Libramiento Norte, Carretera  
Irapuato-León, Irapuato 36821, México.

Correspondence e-mail:  
cathy.lawson@rutgers.edu

## Structure of the *Escherichia coli* RNA polymerase $\alpha$ subunit C-terminal domain

The  $\alpha$  subunit C-terminal domain ( $\alpha$ CTD) of RNA polymerase (RNAP) is a key element in transcription activation in *Escherichia coli*, possessing determinants responsible for the interaction of RNAP with DNA and with transcription factors. Here, the crystal structure of *E. coli*  $\alpha$ CTD ( $\alpha$  subunit residues 245–329) determined to 2.0 Å resolution is reported. Crystals were obtained after reductive methylation of the recombinantly expressed domain. The crystals belonged to space group  $P2_1$  and possessed both pseudo-translational symmetry and pseudo-merohedral twinning. The refined coordinate model ( $R$  factor = 0.193,  $R_{\text{free}}$  = 0.236) has improved geometry compared with prior lower resolution determinations of the  $\alpha$ CTD structure [Jeon *et al.* (1995), *Science*, **270**, 1495–1497; Benoff *et al.* (2002), *Science*, **297**, 1562–1566]. An extensive dimerization interface formed primarily by N- and C-terminal residues is also observed. The new coordinates will facilitate the improved modeling of  $\alpha$ CTD-containing multi-component complexes visualized at lower resolution using X-ray crystallography and electron-microscopy reconstruction.

Received 1 April 2010  
Accepted 18 May 2010

**PDB Reference:** RNA  
polymerase  $\alpha$  subunit  
C-terminal domain, 3k4g.

### 1. Introduction

*Escherichia coli* RNA polymerase (RNAP) is a multisubunit enzyme with core enzyme composition  $\alpha_2\beta\beta'\omega$  and holoenzyme composition  $\alpha_2\beta\beta'\omega\sigma$ . Each  $\alpha$  subunit consists of two independently folded domains: an amino-terminal domain ( $\alpha$ NTD;  $\alpha$  residues 1–235) and a carboxyl-terminal domain ( $\alpha$ CTD;  $\alpha$  residues 250–329). The two domains are connected via a long flexible linker (residues 236–249; Blatter *et al.*, 1994; Negishi *et al.*, 1995; Jeon *et al.*, 1997).  $\alpha$ NTD is responsible for  $\alpha$ -subunit dimerization and for the assembly of the other subunits into a transcriptionally active enzyme (Zhang & Darst, 1998).  $\alpha$ CTD plays a key role in the recruitment of RNAP holoenzyme to promoter DNA (Blatter *et al.*, 1994; Ebright & Busby, 1995). The flexible linker facilitates the independent movement and positioning of  $\alpha$ CTD so that one or two  $\alpha$ CTDs can interact with DNA and/or with one or more transcription factors (Busby & Ebright, 1999).  $\alpha$ CTD binds preferentially to upstream promoter elements (UP elements) that are A/T-rich (Gourse *et al.*, 2000).

The structure of *E. coli*  $\alpha$ CTD was initially determined in solution using NMR spectroscopy, revealing a compact fold with four helices and flexible N- and C-termini (Jeon *et al.*, 1995). The  $\alpha$ CTD structure was subsequently defined at 3.1 Å resolution within a ternary complex consisting of the catabo-

lite activator protein (CAP),  $\alpha$ CTD and DNA using X-ray crystallography (Benoff *et al.*, 2002). In this structure, CAP and  $\alpha$ CTD respectively bind to adjacent CAP and UP-element sites on the DNA, with  $\alpha$ CTD binding to the narrow DNA minor groove of the UP-element A-tract.  $\alpha$ CTD and CAP also make direct contact with each other through a small specific complementary interface.

On *lac* promoter DNA, the interaction between CAP (bound at promoter position  $-61.5$ ) and  $\alpha$ CTD (bound at promoter position  $-42$ ) places  $\alpha$ CTD adjacent to region 4 of the RNAP  $\sigma^{70}$  subunit (bound to the promoter  $-35$  element) and permits functional protein–protein interaction between  $\alpha$ CTD and  $\sigma^{70}$  region 4 (Lawson *et al.*, 2004; Chen *et al.*, 2003; Ross *et al.*, 2003). The expected overall spatial arrangement of CAP,  $\alpha$ CTD,  $\sigma^{70}$  region 4 and DNA was recently confirmed in a 20 Å resolution EM reconstruction of an intact reconstituted CAP–RNAP–promoter DNA complex (Hudson *et al.*, 2009).

Here, we report the first crystallographic structure of free uncomplexed  $\alpha$ CTD ( $\alpha$  residues 245–329) determined at 2.0 Å resolution.

## 2. Materials and methods

### 2.1. Expression and purification of $\alpha$ CTD

Recombinant  $\alpha$ CTD from *E. coli* strain K12 was expressed from pEBT7- $\alpha$ CTD plasmid in *E. coli* BL21 (DE3) (Novagen), which encodes Met followed by  $\alpha$  residues 245–329 (Gaal *et al.*, 1996). Protein expression and purification were performed as described previously by Gaal *et al.* (1996). Briefly, protein was expressed in BL21 (DE3) cells induced with 1 mM IPTG for 4 h at 310 K. The cells were collected by centrifugation at 5000g for 10 min and frozen at 193 K. All subsequent steps were performed at 277 K. Frozen cells were resuspended in 20 ml lysis buffer (50 mM Tris–HCl pH 8.5, 233 mM NaCl, 2 mM EDTA, 0.1 mM DTT, 1 mM  $\beta$ -mercaptoethanol, 5% glycerol, 23  $\mu\text{g ml}^{-1}$  PMSF, 0.5  $\mu\text{g ml}^{-1}$  leupeptin, 1  $\mu\text{g ml}^{-1}$  pepstatin A) and disrupted by sonication. Cell debris was removed by centrifugation at 17 000g for 30 min. A stock solution of 10% (w/v) polyethyleneimine (Sigma) was added to the supernatant to a final concentration of 0.2%; precipitated material was removed by centrifugation at 17 000g for 30 min at 277 K. The supernatant was fractionated using ammonium sulfate, with  $\alpha$ CTD remaining in the supernatant at 35% saturation and precipitating at 100% saturation. The material was resuspended in buffer A (50 mM Tris–HCl pH 8.5, 1 mM EDTA, 0.4 mM DTT), desalted using an Econo-Pac 10DG column (Bio-Rad) and diluted to a volume of 140 ml with buffer A before application onto a HiPrep 16/10 Q XL column (GE Healthcare).  $\alpha$ CTD was eluted with a linear gradient from 0 to 650 mM NaCl and was concentrated to a volume of  $\sim 6$  ml by ultrafiltration (Amicon Ultra-15 with Ultracel 3k membrane, Millipore). The protein was then applied onto a HiLoad 26/60 Superdex 75 gel-filtration column (GE Healthcare) equilibrated with 50 mM Tris–HCl pH 8.0, 0.1 mM EDTA, 0.4 mM DTT, 0.2 M NaCl.  $\alpha$ CTD was eluted in a single peak, concentrated as above to  $\sim 20$ –22 mg ml $^{-1}$ ,

exchanged into buffer WS [20 mM Tris–HCl pH 8.0, 0.1 mM EDTA, 1 mM DTT, 0.2 M NaCl, 0.02% (w/v) NaN<sub>3</sub>] and stored in aliquots at 277 K. Yields were typically 18–20 mg per litre of cell culture.

### 2.2. Cloning, expression and purification of truncated $\alpha$ CTD

The coding sequence for  $\alpha$  residues 249–322 was amplified by PCR from pEBT7- $\alpha$ CTD with forward primer 5'-GTATCCATGGCTTTTCGATCCGATCCTGCTGCG-3' and reverse primer 5'-GACTGGATCCTTATGGCCAGTTTTTCAGGCG-3'. Amplification was performed using *PfuUltra* polymerase for 25 cycles with 30 pmol of each primer. The amplified DNA was digested with *Nco*I and *Bam*HI restriction sites engineered into the 5' and 3' ends of the amplified sequence, respectively, and ligated to the *Nco*I and *Bam*HI sites of the pET-28a(+) bacterial expression vector (Novagen). Expression, purification and storage were as described for  $\alpha$ CTD (245–329). Compared with  $\alpha$ CTD, truncated  $\alpha$ CTD elutes earlier in the HiPrep 16/10 Q XL linear gradient. Truncated  $\alpha$ CTD was stored in aliquots at 277 K at  $\sim 20$  mg ml $^{-1}$ . Yields were typically 45–50 mg per litre of cell culture.

### 2.3. Reductive methylation

Reductive methylation closely followed the protocol of Rayment (1997).  $\alpha$ CTD was exchanged into 50 mM HEPES pH 7.5, 250 mM NaCl using an Econo-Pac 10DG chromatography column (Bio-Rad). 6 ml protein sample (0.5 mg ml $^{-1}$ ) was placed in a 15 ml Falcon tube. 120  $\mu\text{l}$  ABC solution (1 M borane–dimethylamine complex; Sigma–Aldrich product No. 180238) and 240  $\mu\text{l}$  1 M formaldehyde [from 37% (w/v) stock; Sigma–Aldrich product No. 33220] were added to the sample and the reaction was gently agitated for 2 h at 277 K. This last step was then repeated and the reaction was gently agitated for another 2 h period. A final 60  $\mu\text{l}$  of ABC solution was added and the reaction was incubated overnight at 277 K. The reaction was quenched by the addition of 6 mg solid glycine powder. The sample was incubated for an additional 2 h at 277 K. The resulting material was desalted and concentrated by ultrafiltration in buffer WS' [20 mM Tris–HCl pH 8.0, 0.1 mM EDTA, 1 mM DTT, 0.05 M NaCl, 0.02% (w/v) NaN<sub>3</sub>].

### 2.4. Crystallization and data collection

Crystallization screening for  $\alpha$ CTD and truncated  $\alpha$ CTD was performed using hanging-drop vapor diffusion at 289 K with protein concentrations in the range 5–60 mg ml $^{-1}$  and employing five commercial screens (Crystal Screen, Crystal Screen II, PEG/Ion Screen I and II and Natrix; Hampton Research). Additional crystallization screening of truncated  $\alpha$ CTD was performed at the Hauptman–Woodward Institute Center for High Throughput Structural Biology (Luft *et al.*, 2003) with sample concentrations of 10 and 20 mg ml $^{-1}$ .

Crystallization screening of methylated  $\alpha$ CTD ( $\alpha$ CTD<sup>M</sup>) was carried out in MRC crystallization plates (Molecular Dimensions Ltd) using sitting-drop vapor diffusion with the set of commercial screens listed above. Initial incubation was

for four weeks at 289 K; subsequently, plates were transferred to 277 K. Crystals obtained with 0.1 M Na HEPES pH 7.5, 1.4 M sodium citrate tribasic dihydrate (Crystal Screen reagent No. 38, Hampton Research) were soaked in crystallization reservoir solution augmented with 20% glycerol for 1 min prior to mounting on LithoLoops (Molecular Dimensions Inc.) and flash-cooling in liquid nitrogen. Crystals were screened for diffraction quality on Brookhaven National Laboratory National Synchrotron Light Source beamlines X6A and X25. The diffraction data used in the structure determination were collected from a single crystal at 100 K using an ADSC Q270 CCD detector on beamline X6A, with 0.5° rotation per image.

### 2.5. Structure determination, refinement and analysis

Diffraction intensities were initially integrated and scaled assuming primitive orthorhombic lattice symmetry using *DENZO* and *SCALEPACK* (Otwinowski & Minor, 1997). They were subsequently reprocessed assuming primitive monoclinic lattice symmetry using *MOSFLM* and *SCALA* (Leslie, 1992). The search model for molecular replacement trials with *Phaser* (McCoy *et al.*, 2007) was  $\alpha$ CTD from the CAP- $\alpha$ CTD-DNA ternary complex (PDB entry 1lb2, chain B; Benoff *et al.*, 2002). *phenix.xtriage* was used for investigation of Patterson peaks and twinning tests (Adams *et al.*, 2010).

Crystallographic refinement was performed with *phenix.refine* (Adams *et al.*, 2010). Simulated annealing, individual atomic coordinate and individual atom isotropic displacement parameter refinement strategies were performed with non-crystallographic symmetry (NCS) restraints. Manual model adjustment to improve the fit to likelihood-weighted electron-density maps was carried out using *Coot* (Emsley & Cowtan, 2004). In the final refinement cycles NCS restraints were only applied to the peptide backbone. Water molecules were added where supported by both chemistry and geometry with likelihood-weighted difference  $|F_{\text{obs}}| - |F_{\text{calc}}|$  electron density  $>3\sigma$  and likelihood-weighted  $2|F_{\text{obs}}| - |F_{\text{calc}}|$  density  $>1.8\sigma$ . Four metal-ion positions were assigned as  $\text{Na}^+$  based on evaluation of coordination distances (Hsin *et al.*, 2008) and comparison of refined *B*-factor values with neighboring atoms. The structure has been deposited in the PDB with reference code 3k4g.

The quality and stereochemistry of the model were evaluated using *Coot* validation tools and *MolProbity* (Chen *et al.*, 2010). Structural images were generated using *UCSF Chimera* (Pettersen *et al.*, 2004). Accessible surface-area calculations were performed using *PISA* (Krissinel & Henrick, 2007). Secondary-structure identification was performed using *Stride* (Heinig & Frishman, 2004). Sequence-based prediction of preferred *X*-Pro peptide-bond isomerization states was performed using the *PBOND* server (Exarchos *et al.*, 2009).

## 3. Results

### 3.1. $\alpha$ CTD crystallization

An extensive set of crystallization trials was carried out for both  $\alpha$ CTD ( $\alpha$  residues 245–329) and the truncated construct

( $\alpha$  residues 249–322). Even when protein concentrations as high as 60 mg ml<sup>-1</sup> were employed these materials failed to crystallize under any of the trial conditions.

Since the amino-acid composition of  $\alpha$ CTD includes 7% lysine (six of 85 residues), reductive methylation was identified as a possible alternative approach to obtaining a crystal structure of the free uncomplexed domain. Reductive methylation is a simple and efficient method to alter the protein surface properties of a target sample and thereby influence its behavior during crystallization screening (Rayment, 1997; Kim *et al.*, 2008). Methylation of the lysine side-chain amino group reduces its interaction with solvent without altering its intrinsic charge. There are now many examples of proteins that have only crystallized after reductive methylation (Rayment *et al.*, 1993; Schubot & Waugh, 2004; Walter *et al.*, 2006; Au *et al.*, 2008; Kim *et al.*, 2008).

Crystals of dimethyllysine  $\alpha$ CTD ( $\alpha$ CTD<sup>M</sup>) were obtained in Hampton Research Crystal Screen reagent No. 38 (0.1 M Na HEPES pH 7.5, 1.4 M sodium citrate). Single crystals grew after six weeks at 277 K to approximate dimensions of 120 × 120 × 80  $\mu\text{m}$ . It has been reported that methylated proteins usually display reduced solubility (Schubot & Waugh, 2004). The concentration of  $\alpha$ CTD<sup>M</sup> required for crystallization after methylation was as low as 7 mg ml<sup>-1</sup>, with an optimal value of around 17 mg ml<sup>-1</sup>.

### 3.2. Structure solution

The set of molecular-replacement trials leading to successful determination of the  $\alpha$ CTD<sup>M</sup> structure is summarized in Table 1. During the initial processing of the diffraction data primitive orthorhombic lattice symmetry was assumed, with a most probable asymmetric unit content of four  $\alpha$ CTD<sup>M</sup> protomers, but initial molecular-replacement trials encompassing all possible primitive orthorhombic space groups were unsuccessful (Table 1, trial 1). After analysis of the intensity data revealed the presence of a strong off-origin Patterson peak at  $u = 0, v = 0, w = \frac{1}{2}$  with 58% of the origin peak height, indicating pseudo-translational symmetry, a plausible molecular-replacement solution was identified for a primitive orthorhombic lattice with a halved unit-cell *c* repeat (Table 1, trial 2). However, refinement of the reduced-cell solution and the corresponding full-cell solution (created by duplication according to the pseudo-translation vector) stalled at unacceptably high *R* and *R*<sub>free</sub> values.

Pseudo-merohedral twinning can occur in monoclinic crystal systems with special unit-cell geometries, including  $\beta \simeq 90^\circ$  (Hamdane *et al.*, 2009), and in these cases the diffraction patterns of the individual twin domains overlap and the symmetry appears to be that of a higher symmetry space group. To investigate the possibility of pseudo-merohedral twinning, the intensity data were reprocessed as primitive monoclinic, yielding the unit-cell parameters shown in Table 1, trial 3. The second moment of intensities of acentric reflections,  $\langle I^2 \rangle / \langle I \rangle^2$ , which is expected to be 2.0 for untwinned data and 1.5 for twinned data (Yeates, 1997), was 2.35. However, this test can behave anomalously in the presence of

**Table 1**  
 $\alpha$ CTD<sup>M</sup> structure-solution trials.

Trial	Space group	Unit-cell parameters (Å, °)	MR solution LLG ( <i>Phaser</i> )	$\alpha$ CTD <sup>M</sup> protomers per asymmetric unit	Refinement statistics†
1	( <i>P</i> 222)	$a = 51.3, b = 67.6, c = 116.6$	NA	4	NA
2	<i>P</i> 22 <sub>1</sub> 2 <sub>1</sub>	$a = 51.3, b = 67.6, c = 58.3$	106	2	$R_{\text{work}} = 0.47, R_{\text{free}} = 0.51$
3	<i>P</i> 2 <sub>1</sub>	$a = 51.3, b = 67.6, c = 116.6, \beta = 90.1$	4754	8	$R_{\text{work}} = 0.193, R_{\text{free}} = 0.236$

†  $R = \sum_{hkl} ||F_{\text{obs}}| - |F_{\text{calc}}|| / \sum_{hkl} |F_{\text{obs}}|$ , where  $F_{\text{obs}}$  and  $F_{\text{calc}}$  are the observed and calculated structure-factor amplitudes, respectively.  $R_{\text{work}}$  is for reflections from the working set;  $R_{\text{free}}$  was calculated with 4% of the reflections chosen at random and omitted from refinement.

**Table 2**  
 $\alpha$ CTD<sup>M</sup> data collection and refinement.

X-ray source	NLSL X6A
Wavelength (Å)	1.0
Data-collection temperature (K)	100
Resolution range (Å)	47.02–2.05 (2.16–2.05)
Space group	<i>P</i> 2 <sub>1</sub>
Unit-cell parameters (Å)	$a = 51.34, b = 67.61, c = 116.55, \alpha = 90.0, \beta = 90.12, \gamma = 90.0$
Matthews coefficient (Å <sup>3</sup> Da <sup>-1</sup> )	2.63
Solvent content (%)	53.24
No. of measured reflections	187784 (26693)
No. of unique reflections	50235 (7266)
Completeness (%)	99.9 (99.8)
Redundancy	3.7 (3.7)
Mean $I/\sigma(I)$	12.9 (2.1)
$R_{\text{merge}}$ (%)	8.2 (54.4)
Refinement resolution range (Å)	47.02–2.05 (2.10–2.05)
$R_{\text{work}}^{\dagger}$	0.193 (0.261)
$R_{\text{free}}^{\dagger}$	0.237 (0.249)
Reflections, working	50220 (3378)
Reflections, free	2000 (142)
$\alpha$ CTD protomers per asymmetric unit	8
Non-H atoms	5590
Water molecules	322
Average $B$ factor (Å <sup>2</sup> )	31.4
R.m.s.d. bond lengths‡ (Å)	0.003
R.m.s.d. bond angles‡ (°)	0.78
Twinning fraction; operator	0.437; $h, -k, -l$

† Definitions provided in Table 1. ‡ Root-mean-square deviations of bond lengths and bond angles from ideal geometry.

anisotropy, pseudo-centering or pseudo-translational symmetry (Padilla & Yeates, 2003; Brooks *et al.*, 2008). The  $L$ -test, based on deviations in local intensities (Padilla & Yeates, 2003), yielded results that were consistent with pseudo-merohedral twinning:  $|L| = 0.43$  (expected value of 0.500 for untwinned and 0.375 for a perfect twin) and  $L^2 = 0.26$  (0.333 for untwinned and 0.200 for a perfect twin). The twin law found by *phenix.xtriage* was  $h, -k, -l$ , with an estimated twin fraction of 0.42.

The structure was ultimately solved by molecular replacement in space group *P*2<sub>1</sub> using the positioned pair of  $\alpha$ CTD protomers obtained in Table 1, trial 2 as the search model, yielding an initial model with eight independent  $\alpha$ CTD<sup>M</sup> protomers in the crystal asymmetric unit (Table 1, trial 3).

### 3.3. Crystal structure

A refined structural model for the twinned monoclinic  $\alpha$ CTD<sup>M</sup> crystal was obtained with good agreement with the

observed diffraction data ( $R$  factor = 0.193,  $R_{\text{free}} = 0.236$ ; the  $R_{\text{free}}$  test reflections selected automatically by *phenix.refine* obey the highest possible symmetry of the twinned lattice, in this case 222). The 2.0 Å resolution structure provides a complete description of non-H atom positions for residues 246–329 for each of the eight  $\alpha$ CTD<sup>M</sup> protomers in the crystal asymmetric unit. NCS restraints were initially applied to all atoms in each protomer; in the final refinement rounds, eightfold

NCS was only applied to peptide backbone atoms. Final data-processing and refinement statistics are provided in Table 2. The main-chain conformation is identical for each protomer over the entire modeled residue range (Fig. 1*a*); the root-mean-square deviation in C<sup>α</sup>-atom positions after superposition of chains *B–H* on chain *A* ranges from 0.10 to 0.17 Å. Side-chain conformations are also strongly conserved between protomers, with the exception of a few surface-exposed residues. As has been reported previously (Jeon *et al.*, 1995, 1997; Gaal *et al.*, 1996), the domain fold (Fig. 1*b*) includes four  $\alpha$ -helices and two short <sub>310</sub>-helical turns near the  $\alpha$ CTD<sup>M</sup> N-terminus (Fig. 1*b*, blue cylinders).

Owing to the near-atomic resolution of the crystal diffraction data, the refined  $\alpha$ CTD<sup>M</sup> model has improved stereochemistry when compared with prior  $\alpha$ CTD structure determinations, as shown in Table 3. In particular, all peptide bonds of the  $\alpha$ CTD<sup>M</sup> model possess favored Ramachandran  $\varphi/\psi$  combinations, a result that is typically only attainable at near-atomic resolution or better (Chen *et al.*, 2010). In addition, the improved resolution permits more reliable side-chain conformation assignments of the branched residues Thr, Val and Leu (Shapovalov & Dunbrack, 2007). A total of 19 branched side chains have revised conformations in the 2.0 Å structure of  $\alpha$ CTD<sup>M</sup> when compared with the structure determined previously at 3.1 Å resolution (Benoff *et al.*, 2002). The affected residues are indicated by gray ovals in Fig. 1(*b*).

### 3.4. Dimethyllysine residue environments

There are 48 lysine residues in the  $\alpha$ CTD<sup>M</sup> crystal asymmetric unit, six in each  $\alpha$ CTD<sup>M</sup> protomer (Fig. 1*a*, displayed side chains; Fig. 1*b*, cyan ovals). For 39 of the 48 lysine residues electron density is observed for the full side chain, including density consistent with dimethylation of the lysine N<sup>ε</sup> amino N atom. The side chains of the remaining nine lysine residues appear to be disordered, with no electron density present beyond the C<sup>β</sup> atom. Observation of dimethylation at every ordered lysine position is a favorable indication that the reductive methylation reaction essentially proceeded to completion.

The majority of ordered dimethyllysine (mK) side chains (31 of 39) participate in either intradomain contacts or interprotomer crystal contacts (Fig. 2). Residues mK271 and mK304 form intradomain hydrogen-bonded salt bridges with

**Table 3**  
Comparison of  $\alpha$ CTD models.

Structure	$\alpha$ CTD	CAP- $\alpha$ CTD -DNA	$\alpha$ CTD <sup>M</sup>
Reference	Jeon <i>et al.</i> (1995)	Benoff <i>et al.</i> (2002)	This work
$\alpha$ CTD model residue range	249–329	250–321	246–329
Method	NMR	X-ray	X-ray
PDB code (chain ID)	1coo (A)	1lb2 (B)	3k4g (A)
C <sup>α</sup> r.m.s.d.† (Å)	2.93	0.82	—
Ramachandran favored‡ (%)	78.5	75.7	100.0
Ramachandran outliers‡ (%)	1.3	1.4	0.0
Poor side-chain rotamers‡ (%)	33.8	14.1	0.9

† Root-mean-square deviations of common C<sup>α</sup> atoms from  $\alpha$ CTD<sup>M</sup> chain A. ‡ Statistics calculated using *MolProbity* (Chen *et al.*, 2010).

Asp and Glu partners (Figs. 2*a* and 2*b*). The same salt-bridge pairings are present in unmethylated native  $\alpha$ CTD (Benoff *et al.*, 2002). mK298 forms interprotomer salt bridges with Asp/Glu partners (Fig. 2*c*). The mK246 side-chain methylenes participate in interprotomer van der Waals contacts (Fig. 2*d*); mK246 also participates in the crystallographic dimer interface described below.

### 3.5. $\alpha$ CTD<sup>M</sup> dimer

The eight  $\alpha$ CTD<sup>M</sup> protomers in the crystal asymmetric unit are arranged within the lattice as two tetramer units with approximate *D*<sub>2</sub> point symmetry (Fig. 3*a*); each tetramer unit consists of a pair of dimers (Fig. 3*b*). The dimer interface is extensive and buries 1335 Å<sup>2</sup> or 22% of the total accessible surface area of each protomer; in contrast, the dimer–dimer interface within each tetramer buries 435 Å<sup>2</sup> or 7% of the total surface area of each protomer. More than half of the dimer-interface residues are located within the C-terminus (312 and 316–329), with additional residues in the N-terminus (246–254), in the  $\alpha$ 1– $\alpha$ 2 loop (276 and 277) and in helix  $\alpha$ 2 (280). In the dimer, the pair of C-termini associate with each other, forming a short antiparallel  $\beta$ -sheet with a central Na<sup>+</sup> metal-ion-binding site coordinated by two main-chain carbonyl O atoms (residues 320 and 322) in each protomer (Fig. 3*c*).


## 4. Discussion

Recombinant *E. coli* RNA polymerase  $\alpha$  subunit C-terminal domain ( $\alpha$  residues 245–329) is recalcitrant to crystallization in the absence of other macromolecular partners. A truncated fragment, in which the residues that are disordered in the 3.1 Å CAP- $\alpha$ CTD–DNA complex crystal structure of Benoff *et al.* (2002) were removed, also did not yield crystals. However, reductive methylation of the full-length  $\alpha$ CTD construct yielded crystals of a dimethyllysine derivative that diffracted to 2.0 Å resolution. Methylation increased the propensity of  $\alpha$ CTD to form crystals by reducing solubility and by increasing the availability of lysines for the formation of crystal contacts.


Methylated  $\alpha$ CTD assembles into dimers in the monoclinic twinned crystal lattice. At present we do not know whether the observed dimer, which is formed nearly entirely by inter-

actions between N- and C-terminal residues, represents a biologically relevant assembly. Blatter *et al.* (1994) reported that  $\alpha$ CTD prepared by limited proteolysis from whole recombinant  $\alpha$  subunit behaved as a dimer during analytical size-exclusion chromatography, but the residues involved were not identified. There is one dimethyllysine residue in the crystallographic dimer interface (mK246; Fig. 2*d*) but the dimethylamino group does not directly participate in interface formation. There would be no stereochemical barrier to prevent native  $\alpha$ CTD from forming an essentially identical interface, either as an isolated domain or in the context of intact RNAP enzyme.


Formation of the observed dimer does involve discrete conformations of the  $\alpha$ CTD N- and C-termini, including a *trans*-peptide bond between Asp250 and Pro251, a *cis*-peptide bond between Trp321 and Pro322 (Fig. 3*c*, cyan bond) and a *trans*-peptide bond between Pro322 and Pro323. The *PBOND* server (Exarchos *et al.*, 2009) predicts a slight preference for the *cis* conformation (confidence level 0.6) for all three X–Pro peptide bonds based on extended sequence contexts. In the CAP- $\alpha$ CTD–DNA complex described by Benoff and co-workers, electron density for  $\alpha$ CTD is only evident for residues 250–322, thus it is probable that some or all of the X–Pro peptide bonds exist as mixed *cis*–*trans* conformers in this structure. The long incubation period required for formation of  $\alpha$ CTD<sup>M</sup> crystals (six weeks) supports the hypothesis that slow *cis*–*trans* X–Pro conversions accompany the crystallization process. Thermodynamic analysis using the *PISA* server (Krissinel & Henrick, 2007) indicates that once formed the dimer is likely to be stable in solution.



**Figure 1**  
(*a*) The eight chains of the  $\alpha$ CTD<sup>M</sup> crystal asymmetric unit are shown superimposed, with main chains represented as ribbons (gray, loop or turn; blue,  $3_{10}$ -helix; red,  $\alpha$ -helix). Dimethyllysine (mK) residues are also displayed for each chain and are labelled with residue numbers. Regions of  $\alpha$ CTD that interact with CAP, DNA and RNAP  $\sigma$ <sup>70</sup> are outlined. (*b*) The  $\alpha$ CTD primary sequence is shown with  $\alpha$ CTD<sup>M</sup> secondary-structure elements. Lysine positions are indicated with cyan shading. Positions for which branched side-chain rotamer conformations differ between  $\alpha$ CTD<sup>M</sup> (this work) and the lower resolution CAP- $\alpha$ CTD–DNA complex crystal structure (Benoff *et al.*, 2002) are indicated by gray shading.

**Figure 2**

Representative dimethyllysine environments in the  $\alpha\text{CTD}^{\text{M}}$  crystal structure. The refined  $\alpha\text{CTD}^{\text{M}}$  model is shown with likelihood-weighted  $2|F_{\text{obs}}| - |F_{\text{calc}}|$  electron density contoured at  $1.5\sigma$ . (a, b) Intradomain hydrogen-bonded salt bridges. (a) mK271 partners with Asp258 (N–O distance range 2.8–3.2 Å). (b) mK304 partners with Glu286 (N–O distance range 2.6–3.3 Å). (c, d) Interprotomer crystal contacts. (c) mK298 forms interprotomer salt bridges with the Glu248 and Asp250 side chains. (d) mK246 participates in interprotomer van der Waals contacts with the His276 and Tyr277 side chains as well as in solvent-mediated interprotomer hydrogen bonding. The interactions depicted in (a), (b) and (d) are common to all eight  $\alpha\text{CTD}^{\text{M}}$  protomer copies in the crystal asymmetric unit. The interactions depicted in (c) are common to seven of the eight  $\alpha\text{CTD}^{\text{M}}$  protomer copies.

**Figure 3**

$\alpha\text{CTD}^{\text{M}}$  crystal packing. (a) The content of one complete  $P2_1$  unit cell (two crystal asymmetric units with eight  $\alpha\text{CTD}^{\text{M}}$  protomers per asymmetric unit) is shown with the unit cell outlined in green. For reference, one protomer is identified with rainbow coloring (blue, N-terminus; red, C-terminus). The pale red arrow indicates the approximate translational symmetry that gives rise to the Patterson map  $u = 0, v = 0, w = \frac{1}{2}$  pseudo-translation vector. (b)  $\alpha\text{CTD}^{\text{M}}$  crystallographic dimer; a sodium ion positioned at the dimer interface is shown in pink. (c) Metal-ion-binding site formed by  $\alpha\text{CTD}^{\text{M}}$  C-termini at the center of the crystal dimer. O atoms are colored red; N atoms are colored blue; Trp321–Pro322 *cis*-peptide bonds are colored cyan.

Structure determination of methylated  $\alpha$ CTD has yielded a revised high-resolution model with significantly improved stereochemistry compared with prior determinations. The new  $\alpha$ CTD<sup>M</sup> coordinates will facilitate the production of improved models of  $\alpha$ CTD-containing transcription complexes visualized at low resolution, including subassemblies determined using X-ray crystallography and whole complexes determined using electron-microscopy reconstruction. These structures will be described in future publications by our laboratory.

We thank Brian P. Hudson for comments on the manuscript, Helen M. Berman for advice and for providing laboratory space to carry out the work, and Richard H. Ebright for providing the pEBT7- $\alpha$ CTD plasmid and for helpful discussions. NSLS beamline X6A is funded by NIH-NIGMS and NSLS beamline X25 is supported by DOE-OBER and NIH-NCRR. This work was supported by National Institutes of Health GM21589 to CLL.

## References

- Adams, P. D. *et al.* (2010). *Acta Cryst.* **D66**, 213–221.
- Au, K., Ren, J., Walter, T. S., Harlos, K., Nettleship, J. E., Owens, R. J., Stuart, D. I. & Esnouf, R. M. (2008). *Acta Cryst.* **F64**, 327–333.
- Benoff, B., Yang, H., Lawson, C. L., Parkinson, G., Liu, J., Blatter, E., Ebright, R. H., Berman, H. M. & Ebright, R. H. (2002). *Science*, **297**, 1562–1566.
- Blatter, E. E., Ross, W., Tang, H., Gourse, R. L. & Ebright, R. H. (1994). *Cell*, **78**, 889–896.
- Brooks, C. L., Blackler, R. J., Gerstenbruch, S., Kosma, P., Müller-Loennies, S., Brade, H. & Evans, S. V. (2008). *Acta Cryst.* **D64**, 1250–1258.
- Busby, S. & Ebright, R. H. (1999). *J. Mol. Biol.* **293**, 199–213.
- Chen, H., Tang, H. & Ebright, R. H. (2003). *Mol. Cell*, **11**, 1621–1633.
- Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). *Acta Cryst.* **D66**, 12–21.
- Ebright, R. H. & Busby, S. (1995). *Curr. Opin. Genet. Dev.* **5**, 197–203.
- Emsley, P. & Cowtan, K. (2004). *Acta Cryst.* **D60**, 2126–2132.
- Exarchos, K. P., Exarchos, T. P., Papaloukas, C., Troganis, A. N. & Fotiadis, D. I. (2009). *Genomics Proteomics Bioinformatics*, **7**, 138–142.
- Gaal, T., Ross, W., Blatter, E. E., Tang, H., Jia, X., Krishnan, V. V., Assa-Munt, N., Ebright, R. H. & Gourse, R. L. (1996). *Genes Dev.* **10**, 16–26.
- Gourse, R. L., Ross, W. & Gaal, T. (2000). *Mol. Microbiol.* **37**, 687–695.
- Hamdane, D., Lechauve, C., Marden, M. C. & Golinelli-Pimpaneau, B. (2009). *Acta Cryst.* **D65**, 388–392.
- Heinig, M. & Frishman, D. (2004). *Nucleic Acids Res.* **32**, W500–W502.
- Hsin, K., Sheng, Y., Harding, M. M., Taylor, P. & Walkinshaw, M. D. (2008). *J. Appl. Cryst.* **41**, 963–968.
- Hudson, B., Quispe, J., Lara, S., Kim, Y., Berman, H. M., Arnold, E., Ebright, R. E. & Lawson, C. L. (2009). *Proc. Natl Acad. Sci. USA*, **106**, 19830–19835.
- Jeon, Y. H., Negishi, T., Shirakawa, M., Yamazaki, T., Fujita, N., Ishihama, A. & Kyogoku, Y. (1995). *Science*, **270**, 1495–1497.
- Jeon, Y. H., Yamazaki, T., Otomo, T., Ishihama, A. & Kyogoku, Y. (1997). *J. Mol. Biol.* **267**, 953–962.
- Kim, Y. *et al.* (2008). *Nature Methods*, **5**, 853–854.
- Krissinel, E. & Henrick, K. (2007). *J. Mol. Biol.* **372**, 774–797.
- Lawson, C. L., Swigon, D., Murakami, K., Darst, S. A., Berman, H. & Ebright, R. E. (2004). *Curr. Opin. Struct. Biol.* **14**, 10–20.
- Leslie, A. G. W. (1992). *Jnt CCP4/ESF-EACBM Newsl. Protein Crystallogr.* **26**.
- Luft, J. R., Collins, R. J., Fehrman, N. A., Lauricella, A. M., Veatch, C. K. & DeTitta, G. T. (2003). *J. Struct. Biol.* **142**, 170–179.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). *J. Appl. Cryst.* **40**, 658–674.
- Negishi, T., Fujita, N. & Ishihama, A. (1995). *J. Mol. Biol.* **248**, 723–728.
- Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.
- Padilla, J. E. & Yeates, T. O. (2003). *Acta Cryst.* **D59**, 1124–1130.
- Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C. & Ferrin, T. E. (2004). *J. Comput. Chem.* **25**, 1605–1612.
- Rayment, I. (1997). *Methods Enzymol.* **276**, 171–179.
- Rayment, I., Rypniewski, W. R., Schmidt-Base, K., Smith, R., Tomchick, D. R., Benning, M. M., Winkelmann, D. A., Wesenberg, G. & Holden, H. M. (1993). *Science*, **261**, 50–58.
- Ross, W., Schneider, D. A., Paul, B. J., Mertens, A. & Gourse, R. L. (2003). *Genes Dev.* **17**, 1293–1307.
- Schubot, F. D. & Waugh, D. S. (2004). *Acta Cryst.* **D60**, 1981–1986.
- Shapovalov, M. V. & Dunbrack, R. L. Jr (2007). *Proteins*, **66**, 279–303.
- Walter, T. S., Meier, C., Assenberg, R., Au, K. F., Ren, J., Verma, A., Nettleship, J. E., Owens, R. J., Stuart, D. I. & Grimes, J. M. (2006). *Structure*, **14**, 1617–1622.
- Yeates, T. O. (1997). *Methods Enzymol.* **276**, 344–357.
- Zhang, G. & Darst, S. A. (1998). *Science*, **281**, 262–266.